장기 칩(Organ-on-a-Chip) 시장 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Organ-on-a-chip Market Growth & Trends:

The global organ-on-a-chip market size is anticipated to reach USD 952.4 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to register a CAGR of 35.11% from 2025 to 2030. Factors such as the increasing prevalence of chronic disease, the rising need for drug discovery, and growing investment and funding from private and public players are expected to drive the market growth. In addition, increasing competition in the market owing to rising demand from pharmaceutical & biotechnology companies and academic & research institutions is also anticipated to propel the industry growth over the forecast period.

Moreover, the increasing demand for efficient drug discovery techniques, particularly in the context of the rising prevalence of chronic diseases is driving the market growth. For instance, in July 2023, NETRI, in partnership with Axion BioSystems, announced the launch of the NeuroFluidics MEA line. This product line, compatible with Axion's Maestro MultiElectrode Array (MEA) systems, introduces a unique range of compartmentalized microfluidic instruments with an MEA layer. These ready-to-use platforms offer high-throughput solutions for organs-on-chip applications, facilitating advanced research in neurology, dermatology, and other fields crucial for disease study and drug discovery.

Moreover, the liver-on-a-chip segment is a significant driver of the organ-on-a-chip industry, driven by its key role in advancing biomedical research and drug development. For instance, in September 2023, CN Bio, a key player in the organ-on-a-chip industry, collaborated with LifeNet Health LifeSciences, a nonprofit organization recognized globally for its expertise in all-human research solutions. The collaboration aims to supply CN Bio's PhysioMimix OOC range with validated primary human cells from LifeNet Health. In this agreement, LifeNet Health provided supreme-quality, MPS-validated hepatic cells that can be accessed through CN Bio's 'in-a-box' kit for Non-Alcoholic Steatohepatitis (NASH), or directly from LifeNet Health.

Furthermore, North America dominated the organ-on-a-chip industry in 2023 and is projected to grow at the fastest CAGR over the forecast period. The growth is attributed to the presence of key market players in the region and government initiatives. For instance, in March 2023, Bayer AG collaborated with esqLABS and Dynamic42. They introduced a one-year organ-on-a-chip pilot program to reduce testing on animals for drug development in the healthcare industry. Such business initiatives are anticipated to contribute to the growth of the market of the North America region.

Organ-on-a-chip Market Report Highlights:

• The services segment accounted for the largest revenue share of 52.18% in 2024. Segment growth can be attributed to its ability to provide specialized expertise, cost-effectiveness, and comprehensive solutions.
• The drug discovery dominated the market with a revenue share of 62.78% in 2024 due to its key role in advancing preclinical testing.
• North America organ on a chip market has dominated the global market, with a revenue share of 51.97% in 2024.
• Asia Pacific organ-on-a-chip market is anticipated to grow at the fastest rate of 29.11% over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Products & Service Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for personalized medicine
    • 3.2.1.2. Technological advancements in organ-on-a-chip technologies
    • 3.2.1.3. Increasing applications of organ-on-a-chip models in biomedical research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Technical challenges and complexities associated with organ-on-a-chip technique
    • 3.2.2.2. Regulatory hurdles in organ-on-a-chip method
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Products & Service Group Business Analysis

• 4.1. Products & Service Segment Dashboard
• 4.2. Organ-on-a-Chip Market Products & Service Movement Analysis
• 4.3. Organ-on-a-Chip Market Size & Trend Analysis, by Products & Service, 2018 to 2030 (USD Million)
• 4.4. Products
  • 4.4.1. Products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Organ-on-a-Chip Devices
    • 4.4.3.1. Organ-on-a-chip devices market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.2. Liver-on-a-Chip
      • 4.4.3.2.1. Liver-on-a-chip market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.3. Lung-on-a-Chip
      • 4.4.3.3.1. Lung-on-a-chip market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.4. Intestine-on-a-Chip
      • 4.4.3.4.1. Intestine-on-a-chip market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.5. Kidney-on-a-Chip
      • 4.4.3.5.1. Kidney-on-a-chip market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.6. Heart-on-a-Chip
      • 4.4.3.6.1. Heart-on-a-chip market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.7. Others
      • 4.4.3.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Group Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Organ-on-a-Chip Market Application Movement Analysis
• 5.3. Organ-on-a-Chip Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Toxicology Research
  • 5.5.1. Toxicology research market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Organ-on-a-Chip Market End Use Movement Analysis
• 6.3. Organ-on-a-Chip Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Academic & Research Institute
  • 6.5.1. Academic & research institute market estimates and forecasts, 2018-2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by Products & Service, Application, End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
• 7.3. North America
  • 7.3.1. North America Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Target Disease Prevalence
    • 7.3.2.4. U.S. Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Target Disease Prevalence
    • 7.3.3.4. Canada Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Target Disease Prevalence
    • 7.3.4.4. Mexico Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Target Disease Prevalence
    • 7.4.2.4. UK Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Target Disease Prevalence
    • 7.4.3.4. Germany Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Target Disease Prevalence
    • 7.4.4.4. France Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Target Disease Prevalence
    • 7.4.5.4. Italy Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Target Disease Prevalence
    • 7.4.6.4. Spain Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Denmark Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Target Disease Prevalence
    • 7.4.8.4. Sweden Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Target Disease Prevalence
    • 7.4.9.4. Norway Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Japan Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. China Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Target Disease Prevalence
    • 7.5.4.4. India Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Target Disease Prevalence
    • 7.5.5.4. Australia Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Target Disease Prevalence
    • 7.5.6.4. Thailand Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Target Disease Prevalence
    • 7.5.7.4. South Korea Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Target Disease Prevalence
    • 7.6.2.4. Brazil Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Target Disease Prevalence
    • 7.6.3.4. Argentina Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Target Disease Prevalence
    • 7.7.2.4. South Africa Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Target Disease Prevalence
    • 7.7.3.4. Saudi Arabia Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Target Disease Prevalence
    • 7.7.4.4. UAE Organ-on-a-Chip Market, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Target Disease Prevalence
    • 7.7.5.4. Kuwait Organ-on-a-Chip Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Emulate, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. MIMETAS B.V.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Valo Health
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Nortis, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. AxoSim
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. BICO - THE BIO CONVERGENCE COMPANY
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. CN Bio Innovations Ltd
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. The Charles Stark Draper Laboratory, Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. SynVivo, Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. AlveoliX AG
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives